C4 Therapeutics (CCCC) Other financing activities (2020 - 2026)
C4 Therapeutics (CCCC) posted quarterly Other financing activities of $605000.0 for Q1 2026, up 455.05% year-over-year from $109000.0 in Q1 2025, and up 465.42% quarter-over-quarter from $107000.0 in Q3 2025.
C4 Therapeutics (CCCC) Other financing activities (2020 - 2026) Analysis & Trends
C4 Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $605000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 455.05% year-over-year to $605000.0; the TTM figure through Mar 2026 stood at $603000.0 (up 48.16% YoY), while the FY2025 annual figure was $107000.0, down 71.99% from the prior year.
- Other financing activities for Q1 2026 stood at $605000.0, up from $107000.0 in the prior quarter.
- The five-year high for Other financing activities was $605000.0 in Q1 2026, with the low at -$360000.0 in Q4 2022.
- The 5-year median for Other financing activities is $104000.0 (2023), against an average of $117076.9.
- Peak annual rise in Other financing activities reached 8766.67% in 2022, while the deepest fall reached 105.65% in 2022.
- C4 Therapeutics' Other financing activities stood at -$360000.0 in 2022, then soared by 87.22% to -$46000.0 in 2023, then surged by 102.17% to $1000.0 in 2024, then soared by 10600.0% to $107000.0 in 2025, then jumped by 465.42% to $605000.0 in 2026.
- Business Quant data shows CCCC's Other financing activities at $605000.0 in Q1 2026, $107000.0 in Q3 2025, and -$109000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176,000.00 |
| Jun 30, 2026 | 176,000.00 |
| Mar 31, 2026 | 605,000.00 |
| Mar 31, 2026 | 605,000.00 |
| Sep 30, 2025 | 107,000.00 |
| Sep 30, 2025 | 107,000.00 |
| Jun 30, 2025 | -109,000.00 |
| Jun 30, 2025 | -109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Jun 30, 2023 | -46,000.00 |
| Jun 30, 2023 | -46,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Mar 31, 2023 | 104,000.00 |